[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiotherapy-induced-immune-priming\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiotherapy-induced-immune-priming":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100622370","phase-2-a-phase-2-study-of-radiotherapy-induced-immune-priming-to-enhance-elranatamab-elra-in-relapsed-refractory-multiple-myeloma-rrmm-with-extramedullary-disease-emd-and-paramedullary-disease-pmd-prime-emd-pmd-100622370",false,"NCT07382739","A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) \"PRIME-EMD-PMD\"","Inclusion Criteria\n\n* RRMM exposed to IMID, PI, anti-CD38 mAb, relapsed or refractory to at least one prior line of therapy (LOT), progressed on or after the last regimen:\n\n  1. Relapsed disease: progressive disease (PD) \\>60 days after cessation of prior therapy\n  2. Refractory disease: PD \\\u003C=60 days after cessation of prior therapy, \\\u003C25% reduction in paraprotein (monoclonal protein \\[M-protein\\] or serum free light chains \\[sFLC\\]) or measurements of EMD\u002FPMD\n* Diagnosis of relapsed or refractory multiple myeloma as indicated by progression by IMWG criteria\n* At least one locus of EMD or PMD present on imaging (either PET\u002FCT or magnetic resonance imaging \\[MRI\\]):\n* EMD: extramedullary plasmacytoma, not a contiguous extension from a bone lesion.\n* PMD: paraskeletal plasmacytoma, contiguous extension from a bone lesion At least one locus of EMD\u002FPMD that was not previously radiated and can be treated with radiation\n* Hematology (supportive care is allowed, including transfusions and granulocyte colony stimulating factor (G-CSF), if cytopenia is deemed secondary to myeloma disease burden):\n* Hemoglobin (Hgb) \\>=7g\u002FdL\n* Platelet\\>=50K\u002FuL\n* Absolute neutrophil count (ANC) \\>=0.75K\u002FuL\n* Chemistry:\n* Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) \\\u003C=2.5 x upper\n* limit of normal (ULN)\n* Total bilirubin (TBili) \\\u003C=1.5ULN (except for a known history of Gilbert syndrome)\n* Creatinine clearance (CrCL) \\>=30mL\u002Fmin\u002F1.73m2\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) \\\u003C=2, unless ECOG PS due to pain\u002Fmorbidity secondary to underlying myeloma disease, with the potential of improved ECOG PS to \\\u003C=2.\n* All participants must be either\n* Not of childbearing potential, or\n* Practicing at least 1 highly effective method of contraception until 6 months after the last dose of study treatment.\n* Childbearing age female participantsmust have a negative serum pregnancy test at screening and must agree to further pregnancy tests during the study.\n\nExclusion Criteria\n\n1. Prior or concurrent exposure to any of the following in the specified time frame prior to the first dose of Elra treatment:\n\n   * Within 14 days or at least 5 half-lives, whichever is less, of any investigational treatment\n   * Within 7 days of IMIDs, PI, anti-CD38 mAb, or cytotoxic systemic myeloma therapies\n   * Within 12 weeks of autologous stem-cell therapy (ASCT) or 6 months of AlloSCT and has to be off immunosuppressive agents \\>=42 days without signs of graft versus host disease (GVHD)\n   * Within 2 weeks of major surgery\n   * Within 6 months of cerebrovascular accident (CVA) events\n2. Waldenstrom, POEMS, Amyloidosis, ongoing plasma cell leukemia (PCL)\n3. History of Human Immunodeficiency Virus (HIV)\n4. Active, uncontrolled HBV infection despite antiviral therapy.\n5. Uncontrolled cardiac, pulmonary, gastrointestinal (GI), hepatic, renal, central nervous system(CNS) diseases not due to myeloma, at the discretion of investigator, that are not a candidate for T cell engager (TCE) therapy\n6. Uncontrolled or recurrent infections\n7. Autoimmune disease requiring systemic treatment (except for low dose steroids, equivalent to 10mg\u002Fday or less of prednisone)\n8. Disabling psychiatric conditions, substance abuse (alcohol, or drug), dementia, altered mental status\n9. Any other active malignancies within 5 years of completing treatment (with the exception of hormonal therapies for breast or prostate cancer) and \\>minimal risk of recurrence\n10. Myelodysplastic syndromes (MDS)\n11. Any issues that may impair the ability of the participant to receive or tolerate the planned treatment, to understand the informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that would prevent, limit, or confound the protocol specified assessments.\n12. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Elra or other agents used in study.\n13. History or possible non-compliance with recommended treatments","ALL",{"count":17,"type":18},34,"ESTIMATED","INTERVENTIONAL",[21],"PHASE2","To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.",[24,25,26,27,28,29,30],"Phase 2","Radiotherapy-Induced Immune Priming","Elranatamab","Relapsed Refractory Multiple Myeloma (RRMM)","Extramedullary Disease in Multiple Myeloma","Paramedullary Disease","PMD","RECRUITING","2026-04-09",{"date":34,"type":35},"2026-04-14","ACTUAL",{"date":37,"type":35},"2026-03-31",{"date":39,"type":18},"2030-12-31",{"name":41,"class":42},"M.D. Anderson Cancer Center","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":19,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100628895","phase-2-combination-of-high-and-low-dose-radiotherapy-with-immune-therapy-and-tki-in-advanced-colorectal-cancer-a-phase-ii-study-100628895","NCT07467590","Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","Efficacy of Combined High and Low-Dose Radiotherapy With Immune Therapy and Tyrosine Kinase Inhibitors (TKI) as a Second-Line or Later Treatment Strategy for Advanced Colorectal Cancer: A Single-Arm, Open-Label Phase II Study","TRIUNITE-07","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign a written informed consent form.\n2. Age 18-80 years, male or female.\n3. Histologically confirmed microsatellite stable (MSS) \u002F proficient mismatch repair (pMMR) colorectal adenocarcinoma.\n4. Clinical stage IV disease confirmed by systemic imaging. At least two measurable metastatic lesions per RECIST 1.1, including:\n\n   At least one lesion ≥2 cm in diameter and at least one lesion \\\u003C2 cm in diameter;\n\n   For lesions within the same organ, at least one lesion ≥2 cm and one lesion \\\u003C2 cm must be located within independent, non-overlapping radiation fields;\n\n   For lesions in different organs, high-dose and low-dose radiotherapy should preferably be delivered to lesions in different organs.\n\n   Second-line or later treatment setting, defined as disease progression after prior platinum- and irinotecan-based chemotherapy, including:\n5. Failure after first-line triplet chemotherapy containing platinum and irinotecan; Or failure after first-line platinum-based chemotherapy followed by second-line irinotecan-based chemotherapy.\n6. Ability to swallow oral medication.\n7. ECOG performance status 0-1.\n8. Adequate organ function as defined by laboratory criteria.\n\nExclusion Criteria:\n\nDiffuse miliary liver or lung metastases, or bulky metastatic lesions ≥10 cm in diameter.\n\nPresence of brain metastases.\n\n1. History of severe hypersensitivity to monoclonal antibodies or anti-angiogenic agents.\n2. Prior exposure to immune checkpoint inhibitors (including anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies), immune checkpoint agonists (e.g., targeting ICOS, CD40, CD137, GITR, OX40), or any prior cancer immunotherapy.\n3. Active autoimmune disease or history of autoimmune disease, including but not limited to interstitial pneumonitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism (patients on stable hormone replacement therapy may be eligible). Patients with psoriasis or childhood asthma\u002Fallergy that has completely resolved and requires no adult intervention may be eligible; patients requiring bronchodilator therapy are excluded.\n4. History of immunodeficiency, including positive HIV test, congenital or acquired immunodeficiency, prior organ transplantation, or allogeneic bone marrow transplantation.\n5. Uncontrolled cardiovascular disease, including:\n\n   NYHA class II or higher heart failure;\n6. Unstable angina;\n7. Myocardial infarction within 1 year;\n8. Clinically significant uncontrolled supraventricular or ventricular arrhythmias.\n9. Severe infection (CTCAE grade \\>2) within 4 weeks prior to first study treatment, including severe pneumonia, bacteremia, or infection requiring hospitalization. Active pulmonary inflammation on baseline imaging, signs or symptoms of infection within 14 days before treatment requiring systemic antibiotics (except prophylactic antibiotics), or active tuberculosis (current or within 1 year without adequate treatment).\n10. Active hepatitis B (HBV DNA ≥2000 IU\u002FmL) or active hepatitis C (positive HCV antibody with detectable HCV RNA above the lower limit of detection).\n11. Diagnosis of another malignancy within 5 years prior to first study treatment, except for malignancies with low risk of metastasis or death (5-year survival rate \\>90%), such as adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n12. Pregnant or breastfeeding women.","18 Years","80 Years",{"count":55,"type":18},33,[21],"The goal of this clinical trial is to learn whether a high- and low-dose radiotherapy regimen followed by anti-angiogenic TKI and anti-PD-1 antibody therapy works to treat advanced metastatic colorectal cancer. It will also evaluate long-term survival outcomes and explore potential biomarkers associated with tumor response and immune modulation.\n\nThe main questions it aims to answer are:\n\nDoes the high- and low-dose radiotherapy regimen followed by sequential anti-angiogenic TKI and anti-PD-1 therapy improve the objective response rate (ORR) in patients with advanced metastatic colorectal cancer?\n\nWhat are the disease control rate (DCR) and survival outcomes following this treatment strategy?\n\nAre tumor response and long-term survival associated with specific biomarkers related to systemic immune modulation induced by radiotherapy to different metastatic organs?\n\nHow does this radiotherapy pattern affect tumor immune infiltration in metastatic lesions?\n\nThis is a single-arm, single-center, prospective Phase II clinical study designed to evaluate the efficacy of a high- and low-dose radiotherapy regimen targeting metastatic lesions followed by sequential anti-angiogenic TKI and anti-PD-1 antibody therapy in patients with advanced metastatic colorectal cancer.\n\nParticipants will:\n\nReceive high- and low-dose radiotherapy to metastatic lesions. Subsequently receive anti-angiogenic TKI combined with anti-PD-1 antibody therapy.\n\nUndergo regular clinical assessments and imaging evaluations to determine tumor response.\n\nProvide blood and tumor samples for biomarker and immune infiltration analysis. Be followed for survival outcomes and disease progression.",[59,25,60],"Refractory Colorectal Cancer","Immune Response","NOT_YET_RECRUITING","2026-03-09",{"date":64,"type":35},"2026-03-12",{"date":66,"type":18},"2026-04-01",{"date":68,"type":18},"2029-04-01",{"name":70,"class":42},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University"]